OS Therapies Inc (OSTX) 2025 Annual Report – Key Investor Highlights

OS Therapies Inc (NYSE: OSTX) has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The report contains several material developments, strategic milestones, and ongoing financial risks that investors and shareholders need to closely monitor.

Key Financial and Corporate Developments

• Public Float and Outstanding Shares: As of June 30, 2025, OSTX’s public float was approximately \$49.6 million. As of March 26, 2026, the company had 39,533,227 shares of common stock outstanding.
• NYSE American Listing: OSTX common stock is listed on NYSE American under the symbol OSTX.
• Company Structure: OS Therapies is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company.

Recent Financing Activities

• PIPE Financing:
  • On December 24, 2024, OSTX raised approximately \$7.1 million (gross proceeds) via the issuance of Series A Preferred Stock and Series A Warrants.
  • Brookline Capital Markets acted as the exclusive placement agent, receiving fees and warrants.
  • Shareholder approval was received on April 9, 2025, allowing potential dilution above 20% of outstanding common shares to facilitate the transaction.
• Acquisition of HER2 Assets:
  • On April 9, 2025, OSTX completed the acquisition of HER2 assets, aiming to expand its oncology pipeline in osteosarcoma and other indications.
• ATM Equity Offering Program:
  • On August 8, 2025, OSTX entered an at-the-market (ATM) offering agreement with B. Riley Securities and JonesTrading for up to \$18 million in aggregate equity sales.
  • Sales agent commissions are up to 3% of gross sales price.
• Warrant Exercise Inducement and Exchange Offers:
  • Three inducement offerings were completed in 2025, yielding approximately \$11.5 million in gross proceeds.
  • Funds are earmarked for regulatory and pre-commercial efforts for OST-HER2, OS Animal Health spin-off preparations, and general corporate purposes.
• 2026 Bridge Financing:
  • On March 4, 2026, OSTX raised \$2 million (gross) via 10% OID unsecured convertible promissory notes and 1,666,667 warrants (exercise price \$1.40/share, 5-year term). Notes mature March 4, 2027, at 4% annual interest.
  • Funds are intended for clinical development, including ongoing and planned trials, as well as working capital.
  • Placement agent fees include a 7% commission and a \$25,000 expense reimbursement.
• Multiple Registration Commitments:
  • OSTX is committed to filing S-3/S-1 registration statements to register underlying shares from the above financings, subject to deadlines and SEC review.

Financial Stability and Going Concern Risk

• Substantial Doubt About Going Concern:
  • The independent auditor has issued a “going concern” warning. OSTX has significant recurring losses, negative cash flows, and net capital deficiency.
  • The company does not expect to generate revenue in the near term and relies heavily on equity and debt financing to fund operations.
  • Failure to raise substantial additional capital could force the company to delay, scale back, or discontinue drug development or commercialization activities.
• Potential Dilution and Restrictive Financing Terms:
  • Future financings could be dilutive to existing shareholders and may include restrictive covenants or require the relinquishment of rights to certain assets or product candidates.
• Net Operating Loss (NOL) Carryforwards:
  • As of December 31, 2025, OSTX reported federal and state NOLs of approximately \$33.6 million, and tax credits of \$268,568, but their future use may be limited by ownership changes or regulatory factors.

Product Pipeline, Regulatory Progress, and Risks

• Lead Product – OST-HER2:
  • OSTX is advancing OST-HER2 toward regulatory submission for prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma.
  • Proceeds from recent financings are supporting regulatory submissions, clinical development, and pre-commercialization efforts.
• OST-tADC Platform:
  • The company’s next-generation antibody-drug conjugate (tADC) platform remains in preclinical development. Expansion and further development are capital dependent.
• Significant Risks in Drug Development:
  • OSTX is a clinical-stage company with no product revenues and may never become profitable.
  • Drug development is capital intensive, and there are substantial regulatory hurdles and risks of failure in clinical trials, even after promising early results.
  • Delays, non-approval, or adverse findings could materially impact the company’s prospects.
• Regulatory and Global Expansion Risks:
  • OSTX faces additional regulatory burdens, commercial risks, and market acceptance challenges in foreign markets.
  • Risks include differing regulatory requirements, tax and legal compliance, currency fluctuations, political instability, and reduced IP protection.

Intellectual Property and Operational Risks

• Intellectual Property Portfolio:
  • OSTX must maintain, expand, and protect its IP portfolio. Inadequate IP protection or costly litigation could adversely affect the company’s competitive position.
• Operational and Management Risks:
  • The company’s future success is highly dependent on retaining key scientific and management personnel.
  • As a public company, OSTX faces increased compliance costs and regulatory burdens, which could impact financial results and management focus.
• Cybersecurity and Data Protection:
  • Security breaches or IT system failures could disrupt product development and clinical programs.

Summary of Price-Sensitive and Shareholder-Relevant Information

• Ongoing Going Concern Risk: The auditor’s warning and need for substantial additional capital are highly material and may impact market confidence and share price.
• Potential Dilution: Shareholders should be aware of ongoing and future dilutive financings (PIPE, ATM, warrants, convertible notes), which could significantly impact share value.
• Regulatory Milestones: Approval or rejection of OST-HER2, further progress on the OST-tADC platform, and international expansion efforts are likely to have significant effects on the company’s valuation.
• IP and Legal Risks: Any IP litigation or inability to secure patents could adversely affect the company’s competitive position and market potential.

Conclusion

OS Therapies Inc. remains a high-risk, high-potential biopharma company. The coming quarters will be pivotal, with regulatory submissions, capital raises, and ongoing R&D progress all critical to its future. Investors should closely monitor liquidity developments, regulatory progress, and dilution risk, as these are likely to drive volatility in OSTX’s share price.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making any investment decisions. The author and publisher accept no liability for any loss arising from the use of this information.

View OS Therapies Inc Historical chart here